Zeus Capital has acted as nominated adviser and joint broker to Collagen Solutions on its NZ$12m acquisition and £6m placing.
Collagen Solutions is a developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics.
Zeus Capital has advised Collagen since its formation and its admission to AIM in April 2013. The company has been at the heart of its acquisitions of Collbio Limited, a manufacturer of medical grade collagen components, and the acquisition of assets from a US based provider of medical grade bovine collagen.
David Evans, Chairman at Collagen Solutions plc, commented: “The acquisition brings together two highly innovative companies with the potential to secure significant value, in a relatively low-risk environment, by adopting a portfolio approach with regard to development of customers and ensuring revenues are secured long-term by taking them from research and development to manufacturing.”
Ross Andrews, Director, Corporate Finance at Zeus Capital, commented: "Having advised the company since its formation we are delighted to advise on its next stage of development. This acquisition de-risks the company's business model and is a logical strategic extension as well as providing security of high grade collagen supply from a negligible BSE risk country. The Company will now have operational activities at both ends of the supply chain."